[
  {
    "ts": "2026-01-09T20:12:26+00:00",
    "headline": "Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target",
    "summary": "The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme gains attention. Analysts tying the higher target to this theme are effectively saying the model now gives slightly more credit to Viatris’ ability to fit ongoing demand for cost conscious healthcare options as 2026 approaches. Continue reading this article to see how you can keep on top of these...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-viatris-vtrs-201226002.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1ebd0849-d9ff-3a36-9efa-9837e32e7632",
      "content": {
        "id": "1ebd0849-d9ff-3a36-9efa-9837e32e7632",
        "contentType": "STORY",
        "title": "Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target",
        "description": "",
        "summary": "The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme gains attention. Analysts tying the higher target to this theme are effectively saying the model now gives slightly more credit to Viatris’ ability to fit ongoing demand for cost conscious healthcare options as 2026 approaches. Continue reading this article to see how you can keep on top of these...",
        "pubDate": "2026-01-09T20:12:26Z",
        "displayTime": "2026-01-09T20:12:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-viatris-vtrs-201226002.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-viatris-vtrs-201226002.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]